Forecasting the cytokine storm following systematic interleukin (IL)-2 administration

被引：109

作者：

Panelli M.C. ^{[1
]}

White R. ^{[2
]}

Foster M. ^{[2
]}

Martin B. ^{[3
]}

Wang E. ^{[1
]}

Smith K. ^{[1
]}

Marincola F.M. ^{[1
]}

机构：

[1] Immunogenetics Section, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD

[2] Carolinas Medical Center, Charlotte, NC

[3] Unit of Molecular Structure, National Institute of Mental Health, Bethesda, MD

来源：

Journal of Translational Medicine | / 2卷 / 1期

关键词：

Soluble Factor; Renal Cell Cancer; Cytokine Storm; Fourth Dose; Leukocyte Inhibitory Factor;

D O I：

10.1186/1479-5876-2-17

中图分类号：

学科分类号：

摘要：

Extensive clinical experience has shown that systemic interleukin (IL)-2 administration can induce complete or partial regression of renal cell cancer (RCC) metastases in 15 to 20 % of patients. Since IL-2 has no direct anti-cancer effects, it is believed that cancer regression is mediated either by a direct modulation of immune cell effector functions or through the mediation of soluble factors released as a result of IL-2 administration. We previously observed that transcriptional and protein changes induced by systemic IL-2 administration affect predominantly mononuclear phagocytes with little effect, particularly within the tumor microenvironment, on T cell activation, localization and proliferation. It further appeared that mononuclear phagocyte activation could be best explained by the indirect mediation of a secondary release of cytokines by IL-2 responsive cells either in the circulation or in peripheral tissues. © 2004 Panelli et al; licensee BioMed Central Ltd.

引用

页数：14

共 34 条

[31]

Maury C.P., Liljestrom M., Laiho K., Tiitinen S., Kaarela K., Hurme M., Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: Implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis, Arthritis Rheum., 48, pp. 3068-3076, (2003)

[32]

Jin P., Wang E., Polymorphism in clinical immunology. From HLA typing to immunogenetic profiling, J. Transl. Med., 1, (2003)

[33]

Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P., Iyer V., Jeffrey S.S., Van de Rijn M., Waltham M., Pergamenschikov A., Lee J.C., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O., Systematic variation in gene expression patterns in human cancer cell lines, Nature Genetics, 24, pp. 227-235, (2000)

[34]

Locker G.J., Kofler J., Stoiser B., Wilfing A., Wenzel C., Wogerbauer M., Steger G.G., Zielinski C.C., Mader R., Burgmann H., Relation of pro- and anti-inflammatory cytokines and the production of nitric oxide in patients receiving high-dose immunotherapy with interleukin-2, Eur. Cytokine Netw., 11, 3, pp. 391-396, (2000)

← 1 2 3 4 →